Furey Raymond J. 4

What Happened

Raymond J. Furey, EVP, General Counsel, Chief Compliance Officer & Corporate Secretary of Rigel Pharmaceuticals (RIGL), reported a derivative award: 7,394 shares became vested on June 17, 2026. The filing lists the acquisition as $0 because this was the vesting of a performance-based option (not a cash purchase). The option's exercise price is $22.49 per share, implying approximately $166,291 required to exercise all options.

Key Details

• Transaction date: June 17, 2026 (grant/vesting of a performance-based option)
• Report filed: June 22, 2026 (Form 4 — filing was late relative to the usual 2-business-day rule)
• Shares involved: 7,394 derivative shares (optioned)
• Exercise price: $22.49 per share (equal to closing price on original grant date, Jan 29, 2025)
• Shares owned after transaction: Not specified in the provided filing
• Footnotes: (F1) Option originally granted Jan 29, 2025; not reportable until performance condition satisfied. (F2) The option fully vested on June 17, 2026 when the performance metric was met.

Context

This transaction reflects a performance-based option vesting (an award becoming exercisable), not an open-market purchase or sale. No immediate sale or exercise was reported — the option is now vested and can be exercised in the future subject to its terms. Vesting awards are common compensation events and do not by themselves indicate the insider bought or sold stock.